gopubmed logo
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 19 Aug 2016.

Low density lipoprotein receptor

LDL receptor, LDLR, low density lipoprotein receptor
The low density lipoprotein receptor (LDLR) gene family consists of cell surface proteins involved in receptor-mediated endocytosis of specific ligands. Low density lipoprotein (LDL) is normally bound at the cell membrane and taken into the cell ending up in lysosomes where the protein is degraded and the cholesterol is made available for repression of microsomal enzyme 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase, the rate-limiting step in cholesterol synthesis. At the same time, a reciprocal stimulation of cholesterol ester synthesis takes place. Mutations in this gene cause the autosomal dominant disorder, familial hypercholesterolemia. Alternate splicing results in multiple transcript variants.[provided by RefSeq, Sep 2010] (from NCBI)
Top mentioned proteins: PCSK9, HAD, CAN, V1a, ACID
Papers using LDL receptor antibodies
Statin use is associated with improved prostate cancer survival: is it time for a clinical trial?
Agoulnik Irina, In PLoS ONE, 2009
... Antibody for low density lipoprotein receptor (LDLR (EP1553Y)) was from Novus Biologicals, LLC (Littleton, CO, USA) ...
Fibrates down-regulate hepatic scavenger receptor class B type I protein expression in mice
Miyashita Kazuo et al., In Lipids in Health and Disease, 2002
... Anti-SREBP2, anti-LDLR and anti-ABCA1 antibodies were obtained from Abcam (Cambridge, MA, USA) ...
Amyloid beta peptide as a vaccine for Alzheimer's disease involves receptor-mediated transport at the blood-brain barrier.
Khoury Joseph El, In PLoS ONE, 2000
... LDL receptor antibody was from abcam (Cat # ab30532).
Endosomes generate localized Rho–ROCK–MLC2–based contractile signals via Endo180 to promote adhesion disassembly
Isacke Clare M. et al., In The Journal of Cell Biology, 2000
... Mouse anti–human LDLR was obtained from Fitzgerald.
Papers on LDL receptor
LDL receptor-related protein-1 regulates NFκB and microRNA-155 in macrophages to control the inflammatory response.
Gonias et al., Roma, Italy. In Proc Natl Acad Sci U S A, Feb 2016
UNASSIGNED: LDL receptor-related protein-1 (LRP1) is an endocytic and cell-signaling receptor.
Stable Liver-specific Expression of Human IDOL in Humanized Mice Raises Plasma Cholesterol.
Rader et al., Philadelphia, United States. In Cardiovasc Res, Feb 2016
AIMS: IDOL (inducible degrader of the low-density lipoprotein receptor, LDLR), is an E3 ubiquitin ligase that promotes the ubiquitination and degradation of the LDLR.
PAFR in adipose tissue macrophages is associated with anti-inflammatory phenotype and metabolic homeostasis.
Rios et al., São Paulo, Brazil. In Clin Sci (lond), Feb 2016
Regarding metabolic parameters, compared to WT, PAFRKO mice had: i) higher weight gain andserum glucose concentration levels; ii) decreased insulin-stimulated glucose disappearance; iii) insulin resistance in the liver; iv) increased expression of Ldlr in the liver.
Experimental Animal Models Evaluating the Causal Role of Lipoprotein(a) in Atherosclerosis and Aortic Stenosis.
Tsimikas et al., San Diego, United States. In Cardiovasc Drugs Ther, Feb 2016
Mouse models should also ideally be studied in an LDL receptor negative background for atherosclerosis studies, as mice don't develop sufficiently elevated plasma cholesterol to study atherosclerosis in detail.
PCSK9 inhibitors and cardiovascular disease: heralding a new therapeutic era.
PCSK9 Forum ( et al., New York City, United States. In Curr Opin Lipidol, Dec 2015
Removal of circulating PCSK9 increases LDL receptor availability, and thus markedly decreases plasma LDL-C levels (by ∼50-60%), and is additive to the lipid lowering effects of statins and ezetimibe.
Therapeutic Management of Familial Hypercholesterolemia: Current and Emerging Drug Therapies.
Savelloni et al., Philadelphia, United States. In Pharmacotherapy, Dec 2015
Familial hypercholesterolemia (FH) is a genetic disorder characterized by significantly elevated low-density lipoprotein cholesterol (LDL-C) concentrations that result from mutations of the LDL receptor, apolipoprotein B (apo B-100), and proprotein convertase subtilisin/kexin type 9 (PCSK9).
Interplay between CRP, Atherogenic LDL, and LOX-1 and Its Potential Role in the Pathogenesis of Atherosclerosis.
Chen et al., Kao-hsiung, Taiwan. In Clin Chem, Dec 2015
A growing body of evidence has suggested that interplay between CRP, lectin-like oxidized LDL receptor-1 (LOX-1), and atherogenic LDL may underlie the mechanism of endothelial dysfunction that leads to atherosclerosis.
Update on the molecular biology of dyslipidemias.
Ramasamy, Worcester, United Kingdom. In Clin Chim Acta, Dec 2015
Familial hypercholesterolemia is usually due to loss-of-function mutations in LDLR, the gene coding for low density lipoprotein receptor and genes encoding for proteins that interact with the receptor: APOB, PCSK9 and LDLRAP1.
Genome-wide identification of microRNAs regulating cholesterol and triglyceride homeostasis.
Näär et al., United States. In Nat Med, Nov 2015
Several of these miRNAs (miR-128-1, miR-148a, miR-130b, and miR-301b) control the expression of key proteins involved in cholesterol-lipoprotein trafficking, such as the low-density lipoprotein (LDL) receptor (LDLR) and the ATP-binding cassette A1 (ABCA1) cholesterol transporter.
MicroRNA-148a regulates LDL receptor and ABCA1 expression to control circulating lipoprotein levels.
Fernández-Hernando et al., New Haven, United States. In Nat Med, Nov 2015
The hepatic low-density lipoprotein receptor (LDLR) pathway is essential for clearing circulating LDL cholesterol (LDL-C).
Proprotein convertase subtilisin kexin type 9 and high-density lipoprotein metabolism: experimental animal models and clinical evidence.
Ruscica et al., Padova, Italy. In Transl Res, Nov 2015
Several studies have demonstrated its involvement in the regulation of low-density lipoprotein (LDL) cholesterol levels by inducing the degradation of the LDL receptor (LDLR).
Association between familial hypercholesterolemia and prevalence of type 2 diabetes mellitus.
Hovingh et al., Amsterdam, Netherlands. In Jama, Apr 2015
Low-density lipoprotein (LDL) receptor mutations were considered more severe than apolipoprotein B gene (APOB) mutations, and receptor-negative LDL receptor mutations were considered more severe than receptor-deficient mutations.
Exome sequencing identifies rare LDLR and APOA5 alleles conferring risk for myocardial infarction.
Kathiresan et al., Boston, United States. In Nature, Mar 2015
At low-density lipoprotein receptor (LDLR), carriers of rare non-synonymous mutations were at 4.2-fold increased risk for MI; carriers of null alleles at LDLR were at even higher risk (13-fold difference).
Role of Nutraceuticals in Hypolipidemic Therapy.
Averna et al., Palermo, Italy. In Front Cardiovasc Med, 2014
The different nutraceuticals may have different mechanisms of action: inhibition of cholesterol synthesis primarily through action on the enzyme HMG-CoA reductase (policosanol, polyphenols, garlic and, above all, red yeast rice), increase in LDL receptor activity (berberine), reduction of intestinal cholesterol absorption (garlic, plant sterols, probiotics), and also the ability to interfere with bile metabolism (probiotics, guggul).
The LXR-Idol axis differentially regulates plasma LDL levels in primates and mice.
Tontonoz et al., Los Angeles, United States. In Cell Metab, 2014
The LXR-regulated E3 ubiquitin ligase IDOL controls LDLR receptor stability independent of SREBP and PCSK9, but its relevance to plasma lipid levels is unknown.
Menhaden oil decreases high-fat diet-induced markers of hepatic damage, steatosis, inflammation, and fibrosis in obese Ldlr-/- mice.
Jump et al., Corvallis, United States. In J Nutr, 2012
This study showed that plasma and hepatic markers of liver damage, steatosis, inflammation, and fibrosis, but not oxidative stress, were lower in WT and Ldlr(-/-) mice fed menhaden oil in addition to a high-fat diet.
Peroxisome Proliferator-activated receptor γ activation by ligands and dephosphorylation induces proprotein convertase subtilisin kexin type 9 and low density lipoprotein receptor expression.
Han et al., China. In J Biol Chem, 2012
Results indicate that although PPARgamma activation increased PCSK9 expression, PPARgamma activation induced LDLR and CYP7A1 expression that enhanced LDL cholesterol metabolism.
Dihydrotestosterone inhibits lectin-like oxidized-LDL receptor-1 expression in aortic endothelial cells via a NF-κB/AP-1-mediated mechanism.
Yanase et al., Fukuoka, Japan. In Endocrinology, 2012
Dihydrotestosterone inhibits lectin-like oxidized-LDL receptor-1 expression in aortic endothelial cells via a NF-kappaB/AP-1-mediated mechanism
Severe hyperhomocysteinemia promotes bone marrow-derived and resident inflammatory monocyte differentiation and atherosclerosis in LDLr/CBS-deficient mice.
Wang et al., Philadelphia, United States. In Circ Res, 2012
Severe hyperhomocysteinemia promotes bone marrow-derived and resident inflammatory monocyte differentiation and atherosclerosis in LDLr/CBS-deficient mice.
Transcriptional activation of low-density lipoprotein receptor gene by DJ-1 and effect of DJ-1 on cholesterol homeostasis.
Ariga et al., Sapporo, Japan. In Plos One, 2011
DJ-1 participates in metabolism of fatty acid synthesis through transcriptional regulation of the LDLR gene
share on facebooktweetadd +1mail to friends